ARTICLE | Clinical News
Anthim obiltoxaximab regulatory update
June 15, 2015 7:00 AM UTC
FDA accepted a BLA for Anthim obiltoxaximab from Elusys to treat and prevent inhalational anthrax. The PDUFA date is March 18, 2016. The high-affinity humanized mAb against the Bacillus anthracis pro...